JPS584724A - Immunological activating agent - Google Patents

Immunological activating agent

Info

Publication number
JPS584724A
JPS584724A JP10135181A JP10135181A JPS584724A JP S584724 A JPS584724 A JP S584724A JP 10135181 A JP10135181 A JP 10135181A JP 10135181 A JP10135181 A JP 10135181A JP S584724 A JPS584724 A JP S584724A
Authority
JP
Japan
Prior art keywords
xanthan gum
immunological
living body
activating agent
destroying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP10135181A
Other languages
Japanese (ja)
Other versions
JPS6353969B2 (en
Inventor
Fumiyasu Tsuchiya
土屋 文安
Michio Kanbe
道雄 神辺
Munehiro Oda
宗宏 小田
Hideo Hasegawa
秀夫 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
Original Assignee
Meiji Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Milk Products Co Ltd filed Critical Meiji Milk Products Co Ltd
Priority to JP10135181A priority Critical patent/JPS584724A/en
Publication of JPS584724A publication Critical patent/JPS584724A/en
Publication of JPS6353969B2 publication Critical patent/JPS6353969B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:An immunological activating agent, containing xanthan gum as an active constitutent, capable of enhancing the immonulogocal activity of a living body, destroying or checking the growth of cancerous cells, and effective for the viral or bacterial infectious diseases without side effects. CONSTITUTION:An immunological activating agent containing xanthan gum as an active constituent. The xanthan gum consists of glucose, mannose and glucuronic acid as main constitutent saccharides, and is considered to be a straight chain polysaccharide in which the respective constituent saccharides are linked by the beta-linkages and mannose is joined to the glucose at a regular interval as a side chain, and used as a food additive without any toxicity. Furthermore, the xanthan gum is not capable of directly destroying cancerous cells but enhancing the immunological activity of a living body in administration thereto. The activated immunological activity is capable of destroying or checking the growth of the cancerous cells. The very low toxicity of the xanthan gum permits the administration to the living body in a large amount and therefore the immunological activation for a long term. The dose thereof about is 10-10,000mg/ kg/ day.

Description

【発明の詳細な説明】 本発明は、キサ/タンガムを有効成分とする免疫賦活活
性こ関するものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to immunostimulatory activity containing xa/tan gum as an active ingredient.

古くげ、制8削として直接癌細胞を破壊する薬剤がO多
く開発されたこともあった。しかし、直接癌細胞を破壊
する薬剤の多くに、癌細胞を破壊するときに健全細胞を
も破壊してしまい、病気治ゆの真の目的を達成するには
ほど遠いものであった0 そこで、癌細胞に対する生体の抵抗4!i、金利用して
、特異的に癌細胞のみを破壊もしくに静止せしめる治療
法が試みられるようになって来え。ここ(こ用いられる
のが免疫賦活剤といわれるもので、すでに、菌体、細胞
膜、担子菌培養生産物などζこ免疫賦活活性が確認され
1、なかζこけ実用化されているものもみられる。
Many drugs have been developed that directly destroy cancer cells as an antidote. However, many drugs that directly destroy cancer cells also destroy healthy cells when they destroy cancer cells, and are far from achieving the true purpose of curing disease. Resistance of living organisms to cells 4! i. Treatment methods that use gold to specifically destroy or stop cancer cells are beginning to be attempted. The agents used here are called immunostimulants, and their immunostimulatory activity has already been confirmed in bacterial cells, cell membranes, basidiomycete culture products, etc.1, and some have even been put into practical use.

従来の免疫賦活剤に、そのほとんどが新親なものであっ
て、実用化に際して汀、その免疫賦活活性試験とともに
毒性試験にきわめて大きな労力を費さlければならなか
った。
Most of the conventional immunostimulants are new products, and in order to put them into practical use, an extremely large amount of effort had to be spent on immunostimulatory activity tests and toxicity tests.

本発明者らに、公知の無毒性物情のなかから免疫賦活活
性の強い物質金求めて鋭意研究1.たところ、意外にも
キサ/タンガムに強力な免疫賦活活性があることを知っ
た。
The present inventors conducted intensive research to find gold, a substance with strong immunostimulatory activity, from among known non-toxic materials.1. Surprisingly, I learned that Kisa/Tan gum has strong immunostimulatory activity.

キサ/タンガムは、古くから知られた物1M4で、その
毒性は十分試験され、埃在では、毒性が全くないことが
確認され、食品酪加削として認可され、多くの食品に添
加されて、実際憂こ利用されているものである。しかし
ながら、キサツタ/ガムに免疫賦活活性があることに全
く知られ、ず、本発明をもって1矢とするものである。
Kisa/Tan gum is a long-known substance 1M4, and its toxicity has been thoroughly tested and found to be completely non-toxic in the presence of dust.It has been approved as a food dairy product and is added to many foods. In fact, it is being used sparingly. However, it is completely unknown that Japanese vine/gum has immunostimulatory activity, and this is the object of the present invention.

キサ/タンガム(XanLhan Gum ) tTj
、1960年代tこ米国農務省の開発に係るもので、I
JJ在でに米国ケルコ社(Kelco Co、、) i
こおいて大量生産さイ1、ケルトロール(商品名: K
elLrol )の名称で市販されているので、これを
購入すれば、大量入手し得るものである。
XanLhan Gum tTj
, related to the development of the United States Department of Agriculture in the 1960s.
JJ is currently located in the United States, Kelco Co., Ltd.
Mass production here 1. Keltrol (Product name: K
It is commercially available under the name elLrol), so if you purchase it, you can obtain it in large quantities.

筐だ、別途生産しようとすればキサ/トモナス・キャン
 oストリス(XanLhomonas campaa
tris)NIASXl−1−1ffi培養1.て生産
することができる。
It's a box, if you try to produce it separately, it will be XanLhomonas campaa.
tris) NIASXl-1-1ffi culture 1. can be produced.

キサ/トモナス・キャンペストリスNIASXI−1−
1は例えば次の培地へ又は培地Bで、28〜61℃、p
H6〜Z5で通気攪拌培養される。
Kisa/Tomonas campestris NIASXI-1-
1, for example to the next medium or in medium B, at 28-61°C, p.
Aerated agitation culture is carried out at H6 to Z5.

培地A Glucose       2.6%ホエー透析液 
    01% に、HPo、        0.5%Mg5Oa7H
20o、 01% ホエー蛋自分解物   02% pH7,0 培地B Glucose    2% 酵母エキス      0,25% ズブトン       0.5饅 に、T(Po、        0.5%MgSO47
H200,01% pH7,0 得られた培養液は水で希釈し、遠心分離によって菌体及
び不純物全分離除去し、これに多量のアルコールを添加
すること(こまって沈澱物として取得することができる
。得られた沈澱物は加水とアルコール添加をくりかえす
ことをこまって精製することができる。
Medium A Glucose 2.6% whey dialysate
01%, HPo, 0.5%Mg5Oa7H
20o, 01% Whey protein autolysate 02% pH 7.0 Medium B Glucose 2% Yeast extract 0.25% Zubuton 0.5% T(Po, 0.5% MgSO47
H200,01% pH 7,0 The obtained culture solution is diluted with water, all bacterial cells and impurities are separated and removed by centrifugation, and a large amount of alcohol is added to this (this can be obtained as a precipitate). The obtained precipitate can be purified by repeating the addition of water and alcohol.

このよう番こして得られる精製キサンタンガムの性状に
次の通りである。
The properties of the purified xanthan gum obtained by such straining are as follows.

外  観: 黄白色 水   分:  11〜12% 灰   分:  9〜10チ 窒   素:  12% 灰化温度: 470°G 1チ蒸留水溶液での測定値は、次の通りである。Appearance: Yellow-white Water Minutes: 11-12% Ash minutes: 9-10ch Nitrogen: 12% Ashing temperature: 470°G The measured values for the 1-tih distilled aqueous solution are as follows.

屈折率(20℃):  1.3532〜1.3338表
面張力  :  75 dyneArLt′fc、キサ
/り/カムの構造によく解明され、その主壁構成糖にグ
ルコース、マノノース及びグルクロ/酸で、そのナトリ
ウム、カリウム又にカルシウム塩から構成さn、各構成
糖がβ−結合した百聞状の多量体で、マノノースがある
一定間隔でグルコース番こlll1l鎖として結合して
いると考えられている(食品と科学4,1977.92
〜96自)。
Refractive index (20°C): 1.3532-1.3338 Surface tension: 75 dyneArLt'fc, whose structure is well elucidated as xa/li/cam, has glucose, manonose, and glucuro/acid as its main wall constituent sugars. It is a multimer composed of sodium, potassium, or calcium salts, and each constituent sugar is β-linked, and it is thought that manonose is linked at certain intervals as glucose chains (foodstuffs). and Science 4, 1977.92
~96 self).

本発明に、キサンタンガム會有効成分とする免疫賦活削
である。
The present invention uses xanthan gum as an active ingredient for immunostimulation.

キサンタンガムに11接尚細胞を破壊することにできな
いが、生体に投与されれば、生体の免疫活性を畠めるこ
とができる。キサンタンガムによって賦活された免疫力
に癌細胞を破壊もしくに静止することができるものであ
る。また、キサンタンガムによって賦活はれた免疫力に
感染するウィルス、細菌などに対してきわめて有効であ
り、キサンタンガムの生体投与によってウィルス感染症
、細菌感染症を治ゆすることができる。
Although xanthan gum cannot destroy 11-enriched cells, when administered to a living body, it can enhance the immune activity of the living body. The immune force activated by xanthan gum can destroy or stop cancer cells. In addition, it is extremely effective against viruses and bacteria that infect the immune system activated by xanthan gum, and viral and bacterial infections can be cured by administering xanthan gum to living organisms.

キサンタンガム番こよる免疫賦活は、その生体投与後の
インターフェロンの増加lこよって容易に確認すること
ができる。
The immunostimulation caused by xanthan gum can be easily confirmed by the increase in interferon after its administration to living organisms.

木兄明番こ用いるキサンタンガムは毒性が著しるしく低
いために大量生体投与が可能となり、長時間免疫賦活を
行うことができる 投与1は、10〜10000 me
/#/ day程度であり、その削状は散剤、カプセル
剤、水剤、乳剤などで、注射薬、内・服薬、生薬などに
よって投与される。
Since the xanthan gum used here has extremely low toxicity, it can be administered in large quantities to living organisms, and immunostimulation can be carried out for a long period of time.
The shavings are administered in the form of powders, capsules, solutions, emulsions, etc., and are administered by injection, oral medication, and herbal medicine.

次に本発明の実施例を示す。Next, examples of the present invention will be shown.

実施例1 Ehrlich腹水癌に対する結果; ddY系8週令の雌性マウスを用い、1群7匹と(7、
予め1週間ddY系マウスに継代増殖させたEhrli
ch腹水癌細胞を1×1011個腹腔内に移植し、翌日
より連続9日間、対照群lこは生理食塩水を、試験nに
は生理食塩水に溶解したキサンタンガムを腹腔内投与し
た。投与量は125■/ kg / day 。
Example 1 Results for Ehrlich ascites cancer; 8-week-old female ddY mice were used, with 7 mice per group (7,
Ehrli that had been subcultured in ddY mice for one week in advance.
1 x 1011 ch ascites cancer cells were intraperitoneally implanted, and from the next day, physiological saline was administered intraperitoneally to control group I, and xanthan gum dissolved in physiological saline was administered intraperitoneally to test n. The dosage was 125■/kg/day.

25 m9/ kg/ dayおよび50m& / i
cy/ dayおよび50 IQ / kg / da
yの6段階とし友。
25 m9/kg/day and 50m&/i
cy/day and 50 IQ/kg/da
y's 6th stage toshitomo.

キサンタンガムのEhr目Ch腹水癌に対する効果汀、
対照群に対して試験群でどの程度延命したかで判定した
。その結果に第1表に示される。
Effects of xanthan gum on Ehr order Ch ascites cancer,
Judgment was made based on the extent to which survival was prolonged in the test group compared to the control group. The results are shown in Table 1.

第1表 投 与 量 中間生存臼 延 命 率 50日生存対照
  25  100 0/7 12.5    >50    >200  6/72
5   ン50    >200  6/750   
  >50    >200  7/7実施例2 Sarcoma 180腹水癌に対する結果:ddY系
8週令の雌性マウスを用い、1群7匹とし、予め1週間
ddY系マウスに継代増殖させたSarcoma 18
0腹水癌細胞’l1xio’個腹腔内に移植し、翌日よ
り連続9日間、対照群には生理食塩水を、試験群lこは
生理食塩水に溶解したキサ/り/ガムを腹腔内投与した
。投与量に12.5■/kt;/ / day 、 2
5 me/ kg/ dayおよび501n9/kg/
dayの6段階とした。
Table 1 Dosage Intermediate survival rate Survival rate 50-day survival control 25 100 0/7 12.5 >50 >200 6/72
5 N50 >200 6/750
>50 >200 7/7 Example 2 Results against Sarcoma 180 ascites cancer: Sarcoma 18 was subcultured into ddY mice for 1 week in advance using 8-week-old female mice of the ddY strain, with 7 mice per group.
0 ascites cancer cells were implanted intraperitoneally, and from the next day, physiological saline was administered intraperitoneally to the control group, and Kisa/Ri/Gum dissolved in physiological saline was administered intraperitoneally to the test group. . Dosage: 12.5■/kt; / / day, 2
5 me/kg/day and 501n9/kg/
There were six levels of day.

キサ/り/ガムのSarcoma 180腹水癌lこ対
する効果は対照群に対して試験群でどの程度延命したか
で判定した1、その結果は第2表に示される。
The effect of Kisa/Li/Gum on Sarcoma 180 ascites cancer was determined by the extent to which survival was prolonged in the test group compared to the control group1, and the results are shown in Table 2.

第2表 投 辱 量 中間生存臼 延 命 率 50日生存偽V
搾りと)数(日)   (チ)  マウス対照  25
  100 0/7 12.5    41    178  3/725 
    >50    >217  4/750   
  63    143  2/7代理人  弁理士 
 戸 1)親 男
Table 2 Injury amount Intermediate survival rate Life extension rate 50-day survival false V
Squeezing) Number (days) (H) Mouse control 25
100 0/7 12.5 41 178 3/725
>50 >217 4/750
63 143 2/7 Agent Patent Attorney
Door 1) Parent male

Claims (1)

【特許請求の範囲】[Claims] (1)  キ量1−ンタンガムを有効成分とする免疫賦
活剤。
(1) An immunostimulant containing tantan gum as an active ingredient.
JP10135181A 1981-07-01 1981-07-01 Immunological activating agent Granted JPS584724A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10135181A JPS584724A (en) 1981-07-01 1981-07-01 Immunological activating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10135181A JPS584724A (en) 1981-07-01 1981-07-01 Immunological activating agent

Publications (2)

Publication Number Publication Date
JPS584724A true JPS584724A (en) 1983-01-11
JPS6353969B2 JPS6353969B2 (en) 1988-10-26

Family

ID=14298409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10135181A Granted JPS584724A (en) 1981-07-01 1981-07-01 Immunological activating agent

Country Status (1)

Country Link
JP (1) JPS584724A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6053505A (en) * 1983-09-01 1985-03-27 Mitsui Petrochem Ind Ltd Process for polymerizing olefin
WO2005039597A3 (en) * 2003-10-24 2005-07-14 Nutricia Nv Immunemodulating oligosaccharides
WO2008007476A1 (en) * 2006-07-14 2008-01-17 Biomedical Research Group Inc. Method for production of limulus-positive glycolipid, limulus-positive glycolipid, and limulus-positive glycolipid blend

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6053505A (en) * 1983-09-01 1985-03-27 Mitsui Petrochem Ind Ltd Process for polymerizing olefin
JPH0536444B2 (en) * 1983-09-01 1993-05-31 Mitsui Petrochemical Ind
WO2005039597A3 (en) * 2003-10-24 2005-07-14 Nutricia Nv Immunemodulating oligosaccharides
EP1721612A3 (en) * 2003-10-24 2007-05-09 N.V. Nutricia Immunemodulating oligosaccharides
EP2123282A3 (en) * 2003-10-24 2010-01-20 N.V. Nutricia Immunemodulating oligosaccharides
EP2305269A3 (en) * 2003-10-24 2011-07-13 N.V. Nutricia Immunemodulating oligosaccharides
US8557794B2 (en) 2003-10-24 2013-10-15 N.V. Nutricia Immunemodulating oligosaccharides
WO2008007476A1 (en) * 2006-07-14 2008-01-17 Biomedical Research Group Inc. Method for production of limulus-positive glycolipid, limulus-positive glycolipid, and limulus-positive glycolipid blend
US8071758B2 (en) 2006-07-14 2011-12-06 Gen-Ichiro Soma Method for production of limulus-positive glycolipid, the limulus-positive glycolipid, and composition containing the limulus-positive glycolipid
US8471001B2 (en) 2006-07-14 2013-06-25 Gen-Ichiro Soma Method for production of limulus-positive glycolipid, the limulus-positive glycolipid, and composition containing the limulus-positive glycolipid

Also Published As

Publication number Publication date
JPS6353969B2 (en) 1988-10-26

Similar Documents

Publication Publication Date Title
Cooke Acute leukemia in children
JPH08500589A (en) Astragalus Polysaccharide Immunomodulator
US6660722B2 (en) Therapeutical treatments
CN105148253A (en) Antibacterial composition for skin and mucous membrane
Kohn The concentration of coenzyme-like substance in blood following the administration of nicotinic acid to normal individuals and pellagrins
CA2597154C (en) Use of iron(iii) complex compounds
EP0292601A1 (en) Anti aids drug extracted from lentinus edodes
JPS584724A (en) Immunological activating agent
KAUFMAN Trichiniasis: clinical considerations
US11464835B2 (en) Enzyme-treated milk product, preparation method thereof, composition, and products
Mondoa Sugars that Heal: The new healing science of glyconutrients
JPS5815920A (en) Improving agent for biophylactic function
Doe et al. Jejunal pH and folic acid.
DE1792256B2 (en) Orally administered, polyvalent vaccines against local intestinal infections
RU2262350C2 (en) Vaccine for prophylaxis and immunotherapy of human and animal diseases caused by pathogenic and opportunistic gram-negative microorganisms of intestine group and their exotoxins and method for its preparing (variants), immunoglobulin preparation (variant) and method for its preparing, immunobiological preparation polycomponent vaccine
JP4014330B2 (en) Viral infection protection agent
JP2003155249A (en) Immunoglobulin a production promoter
JPH01500751A (en) Treatment method
Bovarnick et al. Rate of excretion of glutamyl polypeptide and its polymers in humans
RU2165253C2 (en) Method of treatment of patients with oncological diseases
JPS6075431A (en) Erythromycin salt and antibiotic-immunoactivator
Masamune et al. Anemia-inducing substances from stomach cancer tissue I. On a dialyzable active substance
KR0133255B1 (en) Health food using mushroom, the preparation process thereof
TWI228991B (en) Pharmaceuticals, foods, beverages, feeds or cosmetics inducing growth factor production
TW206155B (en)